Group 1 - The company has changed its sponsor institution to Ping An Securities for the 2025 private placement of shares, with the original sponsor, Dongfang Securities, transferring its ongoing supervision responsibilities [2] - The company has signed a tripartite supervision agreement with China Minsheng Bank and Ping An Securities to regulate the management and use of raised funds, ensuring the protection of minority investors' rights [2][3] - The total amount raised from the private placement was approximately RMB 820 million, with a net amount of approximately RMB 802 million after deducting issuance costs [2] Group 2 - The tripartite supervision agreement stipulates that the raised funds will be stored in a dedicated account solely for specific projects, including production process efficiency improvements and energy-saving upgrades [3][4] - Ping An Securities will supervise the use of the raised funds and conduct semi-annual inspections of the fund's storage and usage [4][5] - The agreement includes provisions for notification of large withdrawals and compliance with anti-money laundering regulations [5][6] Group 3 - The company has received a new veterinary drug registration certificate for a new inactivated vaccine for swine encephalitis, developed in collaboration with several subsidiaries and partners [14] - The new vaccine is classified as a Class III veterinary drug and is designed to prevent swine encephalitis, with a recommended dosage of 2ml per pig [15][16] - The approval of this new vaccine is expected to enhance the company's product pipeline and strengthen its market position in the animal vaccine sector [20]

Core Viewpoint - The Ministry of Agriculture and Rural Affairs has approved the joint application of Qingdao Weilan Biological Co., Ltd. and other units for "Potassium Penicillin V Soluble Powder" as a new veterinary drug of category five, indicating a significant step in addressing the urgent market demand for effective treatments for necrotic enteritis in chickens [1] Group 1: Product Development - The product is specifically designed for the treatment of necrotic enteritis in chickens, a condition that currently lacks effective treatment options [1] - A total investment of 2.8067 million yuan has been made in the research and development of this product [1] - The product is notable for being usable during the laying period, having a short withdrawal period, high safety, and convenient dosage form [1] Group 2: Market Implications - There is a pressing market demand for medications that can be used during the egg-laying period, highlighting the product's potential to fill a significant gap in the market [1] - The issuance of the new veterinary drug certificate reflects the company's innovative capabilities and is expected to contribute to new revenue growth [1] - The product still requires approval of the product registration number before it can be marketed [1]